1. 530 INTERPRETATION OF HBA1C VALUES IN GERIATRIC PATIENTS WITH TYPE 2 DIABETES: LARGE DIVERGENCE BETWEEN CLINICAL PRACTICE GUIDELINES. (14th June 2021) Authors: Christiaens, A; Boland, B; Henrard, S Journal: Age and ageing Issue: Volume 50(2021)Supplement 2 Page Start: ii1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 530 INTERPRETATION OF HBA1C VALUES IN GERIATRIC PATIENTS WITH TYPE 2 DIABETES: LARGE DIVERGENCE BETWEEN CLINICAL PRACTICE GUIDELINES. (14th June 2021) Authors: Christiaens, A; Boland, B; Henrard, S Journal: Age and ageing Issue: Volume 50(2021)Supplement 2 Page Start: ii1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 74CLASSIFICATION OF OLDER AGE PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TERMS OF SEVERITY AND GLUCOSE LOWERING THERAPY NEEDS USING LATENT CLASS ANALYSIS. (7th February 2019) Authors: Christiaens, A; Hermans, M; Boland, B; Henrard, S Journal: Age and ageing Issue: Volume 48(2019)Supplement 1 Page Start: i20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DOP006 A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease. (16th January 2018) Authors: Meserve, J; Aniwan, S; Koliani-Pace, J L; Shashi, P; Weiss, A; Faleck, D; Winters, A; Chablaney, S; Kochhar, G; Boland, B; Singh, S; Hirten, R; Shmidt, E; Bohm, M; Sagi, S V; Fischer, M; Lukin, D; Hudesman, D; Chang, S; Sultan, K Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S034 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis. (16th January 2018) Authors: Lukin, D; Weiss, A; Aniwan, S; Kadire, S; Tran, G; Rahal, M; Faleck, D; Winters, A; Chablaney, S; Meserve, J; Kochhar, G; Shashi, P; Koliani-Pace, J L; Bohm, M; Sagi, S V; Fischer, M; Boland, B; Singh, S; Hirten, R; Shmidt, E Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S036 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn's disease but not ulcerative colitis: a multi-centre consortium analysis. (16th January 2018) Authors: Faleck, D; Winters, A; Chablaney, S; Shashi, P; Meserve, J; Weiss, A; Aniwan, S; Koliani-Pace, J L; Kochhar, G; Boland, B; Singh, S; Hirten, R; Shmidt, E; Lasch, K; Luo, M; Bohm, M; Sagi, S V; Fischer, M; Hudesman, D; Chang, S Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S066 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. DOP053 Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis. (16th January 2018) Authors: Hudesman, D; Chang, S; Shashi, P; Winters, A; Chablaney, S; Meserve, J; Weiss, A; Aniwan, S; Faleck, D; Koliani-Pace, J L; Kochhar, G; Boland, B; Singh, S; Hirten, R; Shmidt, E; Lasch, K; Luo, M; Bohm, M; Sagi, S V; Fischer, M Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S067 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Equity in prevention and health care. Issue 7 (1st July 2002) Authors: Lorant, V; Boland, B; Humblet, P; Deliège, D Journal: Journal of epidemiology and community health Issue: Volume 56:Issue 7(2002) Page Start: 510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OP022 Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST study. (16th January 2018) Authors: Schreiber, S; Peyrin-Biroulet, L; Boland, B; Higgins, P D; Armuzzi, A; Terdiman, J; Zhou, W; Alperovich, G; Cataldi, F; Goteti, S; Lacerda, A P Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S015 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P281 A serum biomarker panel can accurately identify the presence of mucosal ulcers in patients with Crohn's disease. (15th January 2020) Authors: HOLMER, A; Boland, B; Singh, S; Neill, J; Le, H; Miralles, A; Collins, A; Sandborn, W; Dulai, P Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S292 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗